I now have detailed, comprehensive data from three authoritative sources. Here is the full management:
Preseptal (Periorbital) Cellulitis — Management
Overview
Preseptal cellulitis is an infection of the soft tissues anterior to the orbital septum. It is generally manageable in the outpatient setting, but must be clearly distinguished from postseptal (orbital) cellulitis, which is vision- and life-threatening.
Step 1: Confirm the Diagnosis & Rule Out Orbital Cellulitis
| Feature | Preseptal | Orbital (Postseptal) |
|---|
| Eyelid edema/erythema | ✓ | ✓ |
| Proptosis | ✗ | ✓ |
| Pain on eye movement | ✗ | ✓ |
| Restricted ocular motility | ✗ | ✓ |
| Visual compromise / APD | ✗ | ✓ |
| Chemosis | ✗ | ✓ |
If any orbital features are present → treat as orbital cellulitis (urgent CT + IV antibiotics + hospital admission).
Step 2: Investigations
- History: prior trauma, insect bite, sinusitis, hordeolum, dacryocystitis, prior MRSA, recent healthcare exposure
- Full ocular exam: VA, pupils, EOM, proptosis, fundus
- Vital signs — fever/systemic toxicity?
- Gram stain + culture of any wound/discharge
- CT orbits + sinuses with contrast (axial + coronal) if:
- Orbital cellulitis cannot be excluded
- Significant trauma or suspected foreign body
- Suspected subperiosteal/orbital abscess or sinusitis
- No improvement after 24–48h of oral antibiotics
- CBC + blood cultures in severe cases or if febrile
CT is not routinely required if the exam clearly confirms preseptal involvement only and the patient responds to therapy.
Step 3: Antibiotic Treatment
🟢 Mild Preseptal Cellulitis — Outpatient (Oral) Therapy
Criteria: afebrile, age >5 years, reliable follow-up, no systemic toxicity
First-line (non-MRSA):
| Drug | Adult Dose | Pediatric Dose |
|---|
| Amoxicillin/clavulanate | 875/125 mg PO q12h | 25–45 mg/kg/day in 2 divided doses (max 90 mg/kg/day) |
| Cefpodoxime | 200 mg PO q12h | 10 mg/kg/day in 2 doses (max 400 mg/day) |
| Cefdinir | Standard adult dose | Weight-based dosing |
| Moxifloxacin | 400 mg PO daily | ❌ Contraindicated in children |
If MRSA suspected (risk factors: prior MRSA, recurrent skin infections, healthcare facility exposure in past year, IV drug use, incarceration, hemodialysis, sports with skin contact, poor hygiene):
| Drug | Adult Dose | Pediatric Dose |
|---|
| TMP-SMX (Co-trimoxazole) | 1–2 DS tablets (160/800 mg) PO q12h | 8–12 mg/kg/day TMP + 40–60 mg/kg/day SMX in 2 doses |
| Doxycycline | 100 mg PO b.i.d. | ❌ Contraindicated in children, pregnant/nursing women |
| Clindamycin | 450 mg PO t.i.d. | 10–30 mg/kg/day in 3–4 divided doses |
Duration: 10–14 days for all oral regimens
🔴 Moderate-to-Severe — Inpatient (IV) Therapy
Admit to hospital if ANY of the following:
- Systemically toxic / unwell appearance
- Age ≤5 years
- Possible non-compliance with outpatient treatment
- No improvement or worsening after 24–48h of oral antibiotics
- High fever or bacteremia suspected
IV Regimen:
| Drug | Adult Dose | Pediatric Dose |
|---|
| Vancomycin (MRSA cover) | 0.5–1 g IV q12h (adjust for renal function) | 10–15 mg/kg IV q6h |
| PLUS one of: | | |
| Ampicillin/sulbactam | 3 g IV q6h | 300 mg/kg/day IV in 4 divided doses |
| Piperacillin-tazobactam | 4.5 g IV q6h | 240 mg/kg/day IV in 3 divided doses |
Step 4: Supportive Measures
- Warm compresses to the affected lid
- Treat underlying source (e.g., hordeolum, dacryocystitis, sinusitis)
- Analgesics (e.g., NSAIDs/paracetamol) for pain relief
- If abscess is present → surgical incision and drainage
Step 5: Follow-Up
- Review at 24–48 hours after initiating therapy
- If worsening: obtain CT, escalate to IV antibiotics, reassess for orbital extension or abscess
- Transition from IV to oral once clinically improving
Potential Complications (if untreated/undertreated)
- Abscess formation
- Progression to orbital (postseptal) cellulitis
- Meningitis
- Cavernous sinus thrombosis
- Subperiosteal abscess
— The Wills Eye Manual, pp. 403–409; Kanski's Clinical Ophthalmology 10th Ed., p. 139; Tintinalli's Emergency Medicine, p. 1575